Kornilova E.V., Ermolaeva A.D., Rusanova M.G., Andreev D.A., Davydovskaya M.V., Ermolaeva T.N. et al. [The strategies of drug supply for patients with chronic hepatitis C. Farmakoekonomika]. Modern Pharmacoeconomics and Pharmacoepidemiology 2017; 10(3): 34–46. (In Russ.). DOI: 10.17749/2070-4909.2017.10.3.034-046.

2. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet Gastroenterol Hepatol 2020; (5): 245–66. DOI:10.1016/ S2468-1253(19)30349-8 р.245-266.

3. Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.Н., Волчкова Е.В., Чуланов В.П. Гепатит С и его исходы в России: анализ заболеваемости распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни 2018; 16(3): 37–45. DOI: 10.20953/1729-9225-2018-3-37-45

Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. [Hepatitis C and its outcomes in Russia: an analysis of morbidity, prevalence and mortality before the start of the infection elimination program]. Infectious Diseases 2018; 16(3): 37–45. (In Russ.). DOI: 10.20953/1729-9225-2018-3-37-45.

4. SECURE-Cirrhosis COVID-HEP Combined. https://covidcirrhosis.web. unc.edu/files/2020/07/Weekly-Data-Update-5-July-2020

5. Teti E., Ricciardi A., Antinori A., Galli M., Rizzardini G., Di Biagio A. et al. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. J. Hepatol. 2016; 64(2): 763. DOI:10.1016/S0168-8278(16)01487-2

6. Christensen S., Ingiliz P., Schewe K., Rockstroh J., Hueppe D., Baumgarten A. et al. Relapse and Treatment-Emergent RAVS with DAA-Based Regimens in Hepatitis C Virus (HCV) Mono- or Human Immunodeficiency Virus (HIV)-HCV Co-Infected Patients – a Real Concern in Clinical Practice? Results from the German Hepatitis C Cohort (GECCO). J. Hepatol. 2016; 64(2): 821. DOI:10.1016/S0168-8278(16)01605-6

7. Sarrazin C., Isakov V., Svarovskaia E.S., Hedskog C., Martin R., Chodavarapu K. et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin. Infec.t Dis. 2017; 64: 44–52. DOI: 10.1093/cid/ciw676

8. Carrat F., Fontaine H., Dorival C., Simony M., Diallo A., Hezode C. et al. French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393(10179): 1453–64. DOI: 10.1016/S0140-6736(18)32111-1

9. Mandorfer M., Kozbial K., Schwabl P., Chromy D., Semmler G., Stattermayer A.F. et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interfer-on-free therapy. Hepatology 2020; 71(3): 1023–36. DOI: 10.1002/hep.3088

10. Mauro E., Crespo G., Montironi C., Londono M.C., Hernandez-Gea V., Ruiz P. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018; 67(5): 1683–94. DOI: 10.1002/hep.29557

11. FibroScan & FibroMeter Clinical Handbook Main publications by etiologies & applications, 2017. http://www.echosens.com

12. Морозов В.Г., Фролов А.В., Топорнина Л.М., Синель­ников М.И., Жаркова Е.В., Рыбкина А.А. и др. Эффективность и безопасность противовирусной терапии паритапревир/ритонавир + омбитасвир + дасабувир + рибавирин у больных циррозом печени в исходе хронического гепатита С. Инфекционные болезни 2016; 14(4): 37–43. DOI: 10.20953/1729-9225-2016-4-37-43

Morozov V.G., Frolov A.V., Topornina L. M., Sinelnikov M. I., Zharkova E.V., Rybkina A.A. et al. [Efficacy and safety of antiviral therapy Paritaprevir/ritonavir + Ombitasvir + Dasabuvir + Ribavirin in patients with liver cirrhosis in the outcome of chronic hepatitis C]. Infectious Diseases 2016; 14(4): 37–43. (In Russ.). DOI: 10.20953/1729-9225-2016-4-37-43

13. Davidov Y., Kleinbaum Y., Cohen-Ezra O., Veitsman E., Berdichevski T. et al. Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic Hepatitis C who Achieved Sustained Virologic Response after DAAs Treatment. J. Hepatol. 2016; 64(1): 824–70. \

14. Hametner S., Schwarzer R., Ziachehabi A., Schöfl R., Maieron A. Gastroenterology and Hepatology, Elisabeth Hospital, Linz, Austria. Regression of fibrosis in HCV patients treated with direct acting antivirals (DAAs). J. Hepatol. 2016; 64(1): 958.

15. Макашова В.В., Омарова Х.Г., Понежева Ж.Б. Эффек­тивность препаратов прямого противовирусного действия у больных хроническим гепатитом С. Евразийский Союз Ученых (ЕСУ) 2019; 8(65): 47–9. DOI: 10.31618/ESU.2413-9335.2019.1.65.257

16. Жданов К.В., Козлов К.В., Сукачев В.С., Захаренко С.М., Карякин С.С., Саулевич А.В. Элиминация HCV-инфекции: история с продолжением. Журнал инфектологии 2018; 10(4): 6–13. DOI: 10.22625/2072–6732–2018–10–4–6–13

Zhdanov K.V., Kozlov K.V., Sukachev V.S., Zakharenko S.M., Karyakin S.S., Saulevich A.V. et al. [Elimination of HCV infection: a story with continuation]. J. Infectol. 2018; 10(4): 6–13 (In Russ.). DOI: 10.22625/ 2072-6732-2018-10-4-6-13

17. Эсауленко Е.В., Новак К.Е., Басина В.В., Дземова А.А., Ганченко Р.А. Распространенность коморбидности при хроническом вирусном гепатите С. Медицинский алфавит 2021; (1): 66–70. DOI: 10.33667/2078- 5631-2021-1-66-70

Esaulenko E.V., Novak K.E., Basina V.V., Dzemova A.A., Ganchenko R.A. [The prevalence of comorbidity in chronic viral hepatitis C]. Medical alphabet 2021; (1): 66–70 (In Russ.). DOI:10.33667/2078-5631-2021-1-66-70